Are research peptides legal in the US? No federal law bans them, but selling them for use in people is a crime

No federal law bans research peptides. None is a controlled substance, and a peptide made, sold and bought for laboratory research is a chemical that the federal drug laws do not reach. The same peptide becomes an unapproved drug, and selling it a federal crime, when the evidence shows it is meant for use in people.

That line is drawn by the Federal Food, Drug, and Cosmetic Act, which defines a drug by its intended use rather than by its chemistry. The Food and Drug Administration polices it, reading intended use from everything a seller says and does. Between June 2023 and August 2026, FDA published 19 warning letters to online sellers of peptides labeled for research use. Eleven of them came in 2026, against two in 2025.

Whether a research peptide is legal therefore depends less on the peptide than on the business around it. A label does not settle the question, and neither does the absence of a peptide from the drug schedules. What settles it is the evidence of what the peptide is for, read as a whole by FDA and, in the end, by a court. Since October 2026 a second, narrower channel has opened for compounded peptides, and research material does not enter it.

No research peptide is a federal controlled substance

The Controlled Substances Act's schedules, in 21 CFR part 1308, list the substances whose manufacture, possession and sale need registration with the Drug Enforcement Administration. No peptide appears in them. BPC-157, TB-500, ipamorelin, CJC-1295, epitalon, semax and the other peptides sold for research are absent, as are the obesity-medicine peptides that dominate FDA's recent warning letters. Possessing a research peptide is not a federal drug-possession offense.

One peptide family has its own criminal provision. Section 303(e) of the FD&C Act makes it a felony, punishable by up to five years in prison, to knowingly distribute human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary. The statute defines growth hormone as somatrem, somatropin, or an analogue of either of them, and it authorizes the DEA to investigate. It covers growth hormone itself, not the peptides marketed as stimulating its release.

Absence from the schedules settles less than it seems. Most peptide enforcement in the United States runs through drug law, not narcotics law, and drug law turns on a different question.

A peptide becomes a drug by its intended use

The FD&C Act defines a drug largely by purpose. Section 201(g)(1) covers articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals and articles (other than food) intended to affect the structure or any function of the body of man or other animals. A lyophilized peptide in a vial is none of those things by its chemistry. It becomes one by what it is for.

FDA's regulation on intended use, 21 CFR 201.128, makes that test objective. It does not ask what a seller privately believes.

The intent may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives.

A research-use-only label is one of those expressions, and it counts. It is weighed with everything else: product descriptions, names, what is sold alongside, guides and calculators, social media, replies to customers. The peptide sequence and the purity on the certificate are the same whichever way the evidence points. What "research use only" means in law sets out the statute and the regulation in full.

Once a peptide is a drug, it is almost always a new drug under section 201(p), because no peptide sold for research is generally recognized as safe and effective for any use in people. Section 505(a) forbids introducing a new drug into interstate commerce without an approved application, and section 301(d) makes doing so a prohibited act. There is no research-use exemption in section 505.

How FDA reads intended use on a research peptide seller's website

FDA applies the test by reading websites. The 19 warning letters in this library's FDA enforcement tracker mostly open with a review of the seller's site on stated dates, and the 2026 letters describe no test purchase, sample or inspection. Each quotes the seller's research-use disclaimer and then sets it aside on the rest of the evidence. A letter of March 31, 2026, reference 721806, is typical:

Despite statements on your product labeling marketing your products for "Research Use Only," and "not intended for human consumption, medical use, or veterinary use," evidence obtained from your website establishes that your products are intended to be drugs for human use.

The evidence the letters cite falls into recognizable groups: statements about effects on the body, the same effects introduced as "studied for", clinical-trial results, brand names of approved medicines, coded product names, a solvent sold beside the peptides, syringes and kits, and peptide calculators and guides. No single item decides a case. How the FDA decides what a product is for goes through each, with the letters' own words, and Common mistakes in research-use-only supply lists the business decisions that produce them.

All of this is FDA's interpretation, not settled law. In the agency's own words a warning letter is informal and advisory, and FDA does not consider warning letters to be final agency action. They show how the agency reads the Act and its regulations today, applied to particular facts. A court has the final word, and the agency's reading, its priorities and the regulations themselves can change in either direction.

Selling an unapproved peptide drug is a federal crime

Every prohibited act in section 301 is a crime under section 303(a). A first violation is a misdemeanor, punishable by up to a year in prison, and needs no proof of intent to defraud. A violation committed with the intent to defraud or mislead, or after a prior conviction, is a felony punishable by up to three years for each count.

The record shows these provisions in use against peptide sellers. On July 30, 2026, a federal court in the Northern District of Indiana sentenced the two operators of an online business that sold peptides and other unapproved drugs to 70 months and 16 months in prison. They had pleaded guilty to introducing unapproved drugs into interstate commerce with intent to defraud and mislead. Under the Supreme Court's decisions in United States v. Dotterweich (1943) and United States v. Park (1975), a corporate officer who stands in a responsible relation to a violation can be convicted without proof of personal knowledge.

Short of prosecution, FDA's tools are the warning letter, with its stated risk of seizure and injunction, and the import alert, which lets shipments be held at the border without examination. Private law runs alongside. Between August 12 and October 8, 2026, Eli Lilly filed 11 federal lawsuits against sellers of an experimental obesity-medicine peptide it has not yet brought to market. The claims, under federal false-advertising law and state statutes, have not yet been ruled on. The Lilly lawsuits piece reads every docket.

Compounded peptides: Category 2, the HHS notice and the 503A list

A separate legal channel opened in 2026, and it is the one most of the year's headlines concern. Section 503A of the FD&C Act lets a licensed pharmacy compound a drug for an individual prescription without FDA approval. It may do so only from bulk substances that have a pharmacopeia monograph, are components of approved drugs, or appear on a list FDA makes by regulation, the 503A bulks list.

The 2026 sequence for peptides is short.

The federal compounding record for research peptides, 2026

Date	What happened	What it did
April 15–22	FDA gave notice on April 15, and on April 22 removed BPC-157, TB-500, KPV, MOTS-c, semax, epitalon and six other peptides from Category 2 of its interim bulks policy	Ended their listing as substances raising significant safety risks; authorized nothing
July 23–24	FDA's Pharmacy Compounding Advisory Committee recommended six peptides for the 503A bulks list, against FDA staff advice	A recommendation; the list is changed only by rule
October 30	HHS published a notice that it will not take enforcement action against licensed pharmacies and physicians compounding the six	Enforcement discretion, not binding on HHS or the public; comments close November 13

The HHS notice says it applies while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act (the 503A bulks list) is developed through rulemaking. None of the six is on that list yet. Compounding them is therefore tolerated, not authorized, and only inside a licensed pharmacy, on a prescription, from a registered manufacturer, under conditions set out in our piece on the docket.

None of this changes the status of a research-labeled peptide. The notice covers compounding by state-licensed pharmacies and physicians. A vial sold online as a research chemical is not compounded, not prescribed and not made by a registered drug establishment, and it is exactly where it was before October 30.

State rules on research-grade peptides

States license the pharmacists and physicians who prescribe and compound, and three of them have spoken directly about research-grade peptides. Between May and August 2026, the medical boards of Alabama and South Carolina and three Mississippi boards, among them its pharmacy board, told licensees that under no circumstances is it permissible to compound or dispense a research-grade peptide. Consent forms calling a product research-grade, the boards said, do not reduce a provider's liability. Those notices are set out here.

Louisiana went the other way. Act 374, in force since August 1, 2026, bars the state's licensing boards from prohibiting peptide prescribing and compounding that complies with section 503A. Because the six HHS peptides are not on the 503A bulks list, it is not yet clear that the law reaches them, a question our piece on Act 374 works through. Both kinds of state rule govern professionals in practice. Neither turns a research chemical into a lawful medicine.

Where laboratory research with peptides stands

For a laboratory, the federal position is the one the drug definition implies. A peptide bought for in vitro work, analytical method development or other research that involves no use in people or animals is not being used as a drug. No FDA application, registration or permit is needed to buy it or work with it. The FD&C Act's route for studying an unapproved drug in people is an investigational new drug application under section 505(i) and 21 CFR part 312, with its own sponsor, investigator, review board and consent obligations.

The phrase "research use only" has a defined regulatory meaning in one setting, in vitro diagnostic products, where 21 CFR 809.10(c)(2)(i) requires the statement For Research Use Only. Not for use in diagnostic procedures. For chemicals and peptides sold for research, it has no defined meaning. It is a statement of the seller's intended use, weighed like any other.

The buyer's side of the law is narrower than the seller's but not empty. Section 301(c) makes it a prohibited act to receive a misbranded drug in interstate commerce and deliver it onward. A laboratory buying research material for research is not receiving a drug. A clinic that obtains the same vial to give to people is handling an unapproved drug, and state licensing law, not only federal drug law, governs what a licensed professional may do with it.

How United States peptide law differs from other countries

The American test is unusual in where it looks. The United States asks what the seller intends. Australia schedules some peptides by substance, so that BPC-157 has been a prescription-only Schedule 4 substance since June 1, 2024, whatever the label says. Canada and the United Kingdom define medicines by presentation and by function. How research peptides are regulated around the world sets the five systems side by side, with a page for each country.

What to watch in US peptide law

• The HHS docket. Comments on the peptide compounding policy close November 13, 2026, on docket HHS-OASH-2026-0496. A final policy may change the conditions.
• FDA rulemaking on the 503A bulks list. A final rule adding BPC-157 or any of the other five would make compounding them lawful under section 503A, not merely tolerated.
• The next warning-letter sweep. FDA issued five letters to research-labeled peptide sellers on March 31, 2026, and five more on August 24. The tracker records each as it is posted.
• The intended-use regulation. 21 CFR 201.128 has been revised and re-proposed more than once in recent years; a change to its wording would change how the test is applied.

Frequently asked questions

Are research peptides legal in the United States?

No federal law bans them, and none is a federal controlled substance. A peptide sold and bought for laboratory research is a chemical. It becomes an unapproved drug when the seller's words and conduct show it is intended for use in people, and selling an unapproved drug is a federal crime. This is not legal advice.

Is it legal to buy peptides online?

Buying a research peptide for laboratory research is buying a chemical, and no federal permit is needed. Federal drug law is aimed mainly at sellers, but no peptide sold for research is an approved drug, so a vial used in a person is being used as an unapproved drug whatever its label says. State boards regulate what licensed professionals may do with such material.

Is BPC-157 legal in the US?

BPC-157 is not a controlled substance and is not FDA-approved. As a research chemical it is regulated by intended use like any other peptide. Since October 30, 2026, HHS has said it will not act against licensed pharmacies compounding it under stated conditions, but it is not on the 503A bulks list, and three states bar research-grade peptides from medical practice.

Does a "research use only" label make a peptide legal to sell?

No. It is a statement of intent that FDA weighs against everything else a seller says and does. FDA's warning letters quote such labels and then find, from the rest of the website, that the products were intended for use in people.

Are peptides FDA-approved?

Some peptide medicines are, as specific products from specific companies under approved applications. An approval covers that product, not every vial of the same molecule. No peptide sold for research is an approved drug.

What is the penalty for selling peptides as drugs?

Introducing an unapproved new drug into interstate commerce is a misdemeanor punishable by up to a year in prison, and a felony punishable by up to three years with intent to defraud or mislead. In July 2026 two operators of an online peptide business were sentenced to 70 and 16 months.

Sources & Further Reading

1. Federal Food, Drug, and Cosmetic Act §§ 201(g)(1), 201(p), 301(c), 301(d), 303(a), 303(e), 503A, 505(a), 505(i); 21 U.S.C. §§ 321(g)(1), 321(p), 331(c), 331(d), 333(a), 333(e), 353a, 355(a), 355(i).
2. 21 CFR part 1308, Schedules of Controlled Substances, eCFR edition of October 30, 2026.
3. 21 CFR 201.128, Meaning of "intended uses".
4. Food and Drug Administration. Regulations regarding "intended uses". Final rule. Federal Register 2021;86:41383. August 2, 2021.
5. 21 CFR 809.10(c), Labeling for in vitro diagnostic products.
6. 21 CFR part 312, Investigational new drug application.
7. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letters to online sellers of research-labeled peptides, June 2023 to August 2026, as listed in this library's enforcement tracker.
8. Food and Drug Administration. Regulatory Procedures Manual, Chapter 4: Advisory Actions (Warning Letters and Untitled Letters).
9. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letter, reference 721806. March 31, 2026.
10. United States Attorney's Office, Northern District of Indiana. Sentencing of the operators of an online peptide business, July 30, 2026.
11. United States v. Dotterweich, 320 U.S. 277 (1943).
12. United States v. Park, 421 U.S. 658 (1975).
13. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), notice of April 15, 2026 and revision of April 22, 2026; Pharmacy Compounding Advisory Committee, notice of meeting, 91 FR 20465, April 16, 2026, and meeting of July 23–24, 2026, Docket FDA-2025-N-6895.
14. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. 91 FR 68526, October 30, 2026, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496.
15. Alabama Board of Medical Examiners, May 26, 2026; South Carolina Board of Medical Examiners, August 18, 2026; Mississippi Boards of Medical Licensure, Nursing and Pharmacy, August 19, 2026. Notices on research-grade peptides.
16. Louisiana Act 374 of 2026 (Senate Bill 253), La. R.S. 37:23.5, effective August 1, 2026.
17. Eli Lilly and Company, federal complaints against sellers of an unapproved experimental peptide, August 12 to October 8, 2026, as set out in this library's piece on the lawsuits.

Cosmic Peptides. (2026, November 3). Are research peptides legal in the US? No federal law bans them, but selling them for use in people is a crime. Cosmic Peptides Research Library. Retrieved November 3, 2026, from https://cosmicpeptides.com/research/compliance/are-research-peptides-legal

@misc{cosmicpeptides_research_compliance_are_research_peptides_legal,
  author       = {{Cosmic Peptides}},
  title        = {Are research peptides legal in the US? No federal law bans them, but selling them for use in people is a crime},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/compliance/are-research-peptides-legal},
  urldate      = {2026-11-03},
  note         = {Last reviewed 2026-11-03}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Are research peptides legal in the US? No federal law bans them, but selling them for use in people is a crime
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/03
UR  - https://cosmicpeptides.com/research/compliance/are-research-peptides-legal
Y2  - 2026/11/03
LA  - en
ER  -